Active, not recruitingNCT05224661
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Principal Investigator
- Christopher Hourigan, DM, D.Phil.Virginia Polytechnic Institute and State University
- Intervention
- Prospective determination of the clinical utility of measurable residual disease (MRD) testing(other)
- Enrollment
- 303 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (18)
- City of Hope, Duarte, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Stanford University, Stanford, California, United States
- University of Colorado, Aurora, Colorado, United States
- University of Miami, Miami, Florida, United States
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- Northside Hospital, Atlanta, Georgia, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- New York Presbyterian / Weill Cornell Medical Center, New York, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
National Marrow Donor Program
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05224661 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyJustin Watts, MD
- RECRUITINGPHASE2NCT06557421De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and ConsolidationVirginia Commonwealth University
- RECRUITINGPHASE1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay
- RECRUITINGPHASE2NCT06904482Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodCase Comprehensive Cancer Center
- RECRUITINGNCT07163728Leptin: A Marker for AML Chemo-SensitivityFujian Medical University Union Hospital
- RECRUITINGNANCT06697600A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversUniversity of Rochester
- RECRUITINGPHASE2, PHASE3NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRuijin Hospital